Yeah i'm not sure what you're trying to imply either SoT.
Although what i do recall is Aileron walked in (prior to Roche $1.2B deal) with heavy backing ($40M) from key big pharma GSK, Lily, Novartis & leading VC Apple Tree - key point of this was the CEO & others in the company with their close ties pulling it together.
What i do find interesting though is why would Genentech come out with this in December last year considering Roches current position with Aileron on stapled peptides ?
Stapled Peptides Take a Torpedo From Genentech
Ann: Core patent granted in Australia , page-58
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $461.9M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.8¢ | $362.4K | 3.601M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 18557 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 202544 | 5 |
View Market Depth
| Last trade - 14.07pm 29/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |